{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:22:14Z","timestamp":1791134534446,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,7,30]],"date-time":"2014-07-30T00:00:00Z","timestamp":1406678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s40272-014-0083-3","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T12:46:48Z","timestamp":1406638008000},"page":"363-372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacological Management of Narcolepsy and Cataplexy in Pediatric Patients"],"prefix":"10.1007","volume":"16","author":[{"given":"Michel","family":"Lecendreux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,30]]},"reference":[{"key":"83_CR1","volume-title":"The international classification of sleep disorders, revised: diagnostic and coding manual","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. The international classification of sleep disorders, revised: diagnostic and coding manual. 3rd ed. Rochester: American Academy of Sleep Medicine; 2014.","edition":"3"},{"issue":"9","key":"83_CR2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.5664\/jcsm.3004","volume":"9","author":"T Roth","year":"2013","unstructured":"Roth T, Dauvilliers Y, Mignot E, Montplaisir J, Paul J, Swick T, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9(9):955\u201365.","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"83_CR3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/sleep\/25.2.197","volume":"25","author":"MH Silber","year":"2002","unstructured":"Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep. 2002;25(2):197\u2013202.","journal-title":"Sleep"},{"issue":"1","key":"83_CR4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/sleep\/30.1.13","volume":"30","author":"WT Longstreth Jr","year":"2007","unstructured":"Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007;30(1):13\u201326.","journal-title":"Sleep"},{"issue":"2","key":"83_CR5","doi-asserted-by":"crossref","first-page":"e1003270","DOI":"10.1371\/journal.pgen.1003270","volume":"9","author":"J Faraco","year":"2013","unstructured":"Faraco J, Lin L, Kornum BR, Kenny EE, Trynka G, Einen M, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet. 2013;9(2):e1003270.","journal-title":"PLoS Genet"},{"issue":"3","key":"83_CR6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ana.1130","volume":"50","author":"S Nishino","year":"2001","unstructured":"Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol. 2001;50(3):381\u20138.","journal-title":"Ann Neurol"},{"key":"83_CR7","doi-asserted-by":"crossref","unstructured":"De la Herr\u00e1n-Arita AK et al. CD4+ T cell autoimmunity to hypocretin\/orexin and cross-reactivity to a 2009 H1N1 influenza a epitope in narcolepsy. Sci Transl Med. 2013;5:216ra176. doi: 10.1126\/scitranslmed.3007762","DOI":"10.1126\/scitranslmed.3007762"},{"issue":"3","key":"83_CR8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11910-010-0101-y","volume":"10","author":"P Bonnavion","year":"2010","unstructured":"Bonnavion P, de Lecea L. Hypocretins in the control of sleep and wakefulness. Curr Neurol Neurosci Rep. 2010;10(3):174\u20139.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"83_CR9","doi-asserted-by":"crossref","unstructured":"Baimel C, Bartlett SE, Chiou LC, Lawrence AJ, Muschamp JW, Patkar O, et al. Orexin\/hypocretin role in reward: implications for opioid and other addictions. Br J Pharmacol. Epub 15 Feb 2014.","DOI":"10.1111\/bph.12639"},{"issue":"11","key":"83_CR10","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1212\/WNL.57.11.2029","volume":"57","author":"Y Dauvilliers","year":"2001","unstructured":"Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, Besset A, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;57(11):2029\u201333.","journal-title":"Neurology"},{"issue":"1","key":"83_CR11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/sleep\/25.1.27","volume":"25","author":"ML Okun","year":"2002","unstructured":"Okun ML, Lin L, Pelin Z, Hong S, Mignot E. Clinical aspects of narcolepsy\u2013cataplexy across ethnic groups. Sleep. 2002;25(1):27\u201335.","journal-title":"Sleep"},{"key":"83_CR12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2013.02.003","volume":"43","author":"AK Singh","year":"2013","unstructured":"Singh AK, Mahlios J, Mignot E. Genetic association, seasonal infections and autoimmune basis of narcolepsy. J Autoimmun. 2013;43:26\u201331.","journal-title":"J Autoimmun"},{"key":"83_CR13","first-page":"792687","volume":"2014","author":"AK Herran-Arita De la","year":"2014","unstructured":"De la Herran-Arita AK, Garcia-Garcia F. Narcolepsy as an immune-mediated disease. Sleep Disord. 2014;2014:792687.","journal-title":"Sleep Disord"},{"issue":"Pt 12","key":"83_CR14","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1093\/brain\/awt277","volume":"136","author":"F Pizza","year":"2013","unstructured":"Pizza F, Franceschini C, Peltola H, Vandi S, Finotti E, Ingravallo F, et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain. 2013;136(Pt 12):3787\u201395.","journal-title":"Brain"},{"issue":"2","key":"83_CR15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5665\/sleep.2366","volume":"36","author":"F Poli","year":"2013","unstructured":"Poli F, Pizza F, Mignot E, Ferri R, Pagotto U, Taheri S, et al. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep. 2013;36(2):175\u201381.","journal-title":"Sleep"},{"issue":"10","key":"83_CR16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1212\/01.wnl.0000216142.21375.71","volume":"66","author":"G Plazzi","year":"2006","unstructured":"Plazzi G, Parmeggiani A, Mignot E, Lin L, Scano MC, Posar A, et al. Narcolepsy\u2013cataplexy associated with precocious puberty. Neurology. 2006;66(10):1577\u20139.","journal-title":"Neurology"},{"issue":"7","key":"83_CR17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/cns.12105","volume":"19","author":"CO Inocente","year":"2013","unstructured":"Inocente CO, Lavault S, Lecendreux M, Dauvilliers Y, Reimao R, Gustin MP, et al. Impact of obesity in children with narcolepsy. CNS Neurosci Ther. 2013;19(7):521\u20138.","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"83_CR18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.sleep.2003.10.006","volume":"5","author":"S Kotagal","year":"2004","unstructured":"Kotagal S, Krahn LE, Slocumb N. A putative link between childhood narcolepsy and obesity. Sleep Med. 2004;5(2):147\u201350.","journal-title":"Sleep Med"},{"issue":"3","key":"83_CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1515\/JPEM.2010.23.3.257","volume":"23","author":"MP Perriol","year":"2010","unstructured":"Perriol MP, Cartigny M, Lamblin MD, Poirot I, Weill J, Derambure P, et al. Childhood-onset narcolepsy, obesity and puberty in four consecutive children: a close temporal link. J Pediatr Endocrinol Metab. 2010;23(3):257\u201365.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"11","key":"83_CR20","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/sleep\/33.11.1457","volume":"33","author":"A Aran","year":"2010","unstructured":"Aran A, Einen M, Lin L, Plazzi G, Nishino S, Mignot E. Clinical and therapeutic aspects of childhood narcolepsy\u2013cataplexy: a retrospective study of 51 children. Sleep. 2010;33(11):1457\u201364.","journal-title":"Sleep"},{"key":"83_CR21","doi-asserted-by":"crossref","unstructured":"Posar A, Pizza F, Parmeggiani A, Plazzi G. Neuropsychological findings in childhood narcolepsy. J Child Neurol. Epub 2013 Nov 28.","DOI":"10.1177\/0883073813508315"},{"issue":"1","key":"83_CR22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.sleep.2013.09.018","volume":"15","author":"YS Huang","year":"2014","unstructured":"Huang YS, Guilleminault C, Chen CH, Lai PC, Hwang FM. Narcolepsy\u2013cataplexy and schizophrenia in adolescents. Sleep Med. 2014;15(1):15\u201322.","journal-title":"Sleep Med"},{"issue":"5","key":"83_CR23","first-page":"631","volume":"31","author":"K Sonka","year":"2010","unstructured":"Sonka K, Kemlink D, Buskova J, Pretl M, Srutkova Z, Maurovich Horvat E, et al. Obesity accompanies narcolepsy with cataplexy but not narcolepsy without cataplexy. Neuro Endocrinol Lett. 2010;31(5):631\u20134.","journal-title":"Neuro Endocrinol Lett"},{"issue":"4","key":"83_CR24","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2006-0647","volume":"118","author":"G Stores","year":"2006","unstructured":"Stores G, Montgomery P, Wiggs L. The psychosocial problems of children with narcolepsy and those with excessive daytime sleepiness of uncertain origin. Pediatrics. 2006;118(4):e1116\u201323.","journal-title":"Pediatrics"},{"issue":"3","key":"83_CR25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/17518420802011493","volume":"11","author":"L Dorris","year":"2008","unstructured":"Dorris L, Zuberi SM, Scott N, Moffat C, McArthur I. Psychosocial and intellectual functioning in childhood narcolepsy. Dev Neurorehabil. 2008;11(3):187\u201394.","journal-title":"Dev Neurorehabil"},{"issue":"1","key":"83_CR26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.sleep.2010.02.017","volume":"12","author":"R Peraita-Adrados","year":"2011","unstructured":"Peraita-Adrados R, Garcia-Penas JJ, Ruiz-Falco L, Gutierrez-Solana L, Lopez-Esteban P, Vicario JL, et al. Clinical, polysomnographic and laboratory characteristics of narcolepsy\u2013cataplexy in a sample of children and adolescents. Sleep Med. 2011;12(1):24\u20137.","journal-title":"Sleep Med"},{"issue":"3","key":"83_CR27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.sleep.2013.08.798","volume":"15","author":"CO Inocente","year":"2014","unstructured":"Inocente CO, Gustin MP, Lavault S, Guignard-Perret A, Raoux A, Christol N, et al. Depressive feelings in children with narcolepsy. Sleep Med. 2014;15(3):309\u201314.","journal-title":"Sleep Med"},{"issue":"6","key":"83_CR28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.sleep.2013.03.002","volume":"14","author":"MM Ohayon","year":"2013","unstructured":"Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013;14(6):488\u201392.","journal-title":"Sleep Med"},{"key":"83_CR29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.sleep.2014.01.015","volume":"15","author":"MJ Thorpy","year":"2014","unstructured":"Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014;15:502\u20137.","journal-title":"Sleep Med"},{"issue":"3","key":"83_CR30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5664\/jcsm.27493","volume":"5","author":"P Jennum","year":"2009","unstructured":"Jennum P, Knudsen S, Kjellberg J. The economic consequences of narcolepsy. J Clin Sleep Med. 2009;5(3):240\u20135.","journal-title":"J Clin Sleep Med"},{"key":"83_CR31","doi-asserted-by":"crossref","unstructured":"Inocente CO, Gustin MP, Lavault S, Guignard-Perret A, Raoux A, Christol N, et al. Quality of life in children with narcolepsy. CNS Neurosci Ther. 2014. [Epub ahead of print].","DOI":"10.1111\/cns.12291"},{"key":"83_CR32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jsmc.2014.03.001","volume":"9","author":"M Lecendreux","year":"2014","unstructured":"Lecendreux M. Quality of life in children with narcolepsy and cataplexy. Sleep Med Clin. 2014;9:211\u20137","journal-title":"Sleep Med Clin."},{"issue":"6","key":"83_CR33","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.20339","volume":"56","author":"Y Dauvilliers","year":"2004","unstructured":"Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004;56(6):905\u20138.","journal-title":"Ann Neurol"},{"issue":"10","key":"83_CR34","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00415-008-0983-7","volume":"255","author":"G Plazzi","year":"2008","unstructured":"Plazzi G, Poli F, Franceschini C, Parmeggiani A, Pirazzoli P, Bernardi F, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol. 2008;255(10):1549\u201354.","journal-title":"J Neurol"},{"issue":"2","key":"83_CR35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.chc.2007.11.010","volume":"17","author":"B Vitiello","year":"2008","unstructured":"Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008;17(2):459\u201374.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"3","key":"83_CR36","first-page":"293","volume":"3","author":"T Rugino","year":"2007","unstructured":"Rugino T. A review of modafinil film-coated tablets for attention-deficit\/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat. 2007;3(3):293\u2013301.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"83_CR37","unstructured":"Provigil\u00ae [modafinil] tablets US prescribing information. Frazer: Cephalon, Inc.; 2010."},{"key":"83_CR38","unstructured":"Nuvigil\u00ae [armodafinil] tablets US prescribing information. Frazer: Cephalon, Inc.; 2010."},{"issue":"5","key":"83_CR39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00004583-199905000-00012","volume":"38","author":"B Geller","year":"1999","unstructured":"Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38(5):513\u20136.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"83_CR40","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1468-1331.2006.01473.x","volume":"13","author":"M Billiard","year":"2006","unstructured":"Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol. 2006;13(10):1035\u201348.","journal-title":"Eur J Neurol"},{"issue":"12","key":"83_CR41","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","volume":"30","author":"TI Morgenthaler","year":"2007","unstructured":"Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705\u201311.","journal-title":"Sleep"},{"key":"83_CR42","volume-title":"Principles and practice of sleep medicine","author":"C Guilleminault","year":"2011","unstructured":"Guilleminault C, Fromherz S. Narcolepsy: diagnosis and management. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th ed. St. Louis: Elsevier; 2011.","edition":"5"},{"issue":"4","key":"83_CR43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13311-012-0150-9","volume":"9","author":"EJ Mignot","year":"2012","unstructured":"Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739\u201352.","journal-title":"Neurotherapeutics"},{"key":"83_CR44","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/B978-0-444-52910-7.00003-9","volume":"112","author":"M Lecendreux","year":"2013","unstructured":"Lecendreux M. Pediatric narcolepsy: clinical and therapeutical approaches. Handb Clin Neurol. 2013;112:839\u201345.","journal-title":"Handb Clin Neurol"},{"key":"83_CR45","doi-asserted-by":"crossref","unstructured":"Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000;54(5):1166\u201375.","DOI":"10.1212\/WNL.54.5.1166"},{"issue":"4","key":"83_CR46","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1185\/030079906X100050","volume":"22","author":"JR Harsh","year":"2006","unstructured":"Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761\u201374.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"83_CR47","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/sleep\/29.7.939","volume":"29","author":"J Black","year":"2006","unstructured":"Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939\u201346.","journal-title":"Sleep"},{"issue":"6","key":"83_CR48","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1389-9457(03)00162-X","volume":"4","author":"A Ivanenko","year":"2003","unstructured":"Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med. 2003;4(6):579\u201382.","journal-title":"Sleep Med"},{"issue":"Suppl","key":"83_CR49","first-page":"A88","volume":"30","author":"J Owens","year":"2007","unstructured":"Owens J, Bogan R, Lankford A, Sheldon S. Modafinil is well tolerated in children and adolescents with excessive sleepiness and obstructive sleep apnea: a 6- week double blind study [abstract]. Sleep. 2007;30(Suppl):A88\u20139.","journal-title":"Sleep"},{"issue":"4","key":"83_CR50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2869.2011.00991.x","volume":"21","author":"M Lecendreux","year":"2012","unstructured":"Lecendreux M, Bruni O, Franco P, Gringras P, Konofal E, Nevsimalova S, et al. Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. J Sleep Res. 2012;21(4):481\u20133.","journal-title":"J Sleep Res"},{"issue":"2","key":"83_CR51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.sleep.2003.11.002","volume":"5","author":"US Xyrem","year":"2004","unstructured":"Xyrem US, Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5(2):119\u201323.","journal-title":"Sleep Med"},{"issue":"5","key":"83_CR52","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.sleep.2005.03.010","volume":"6","author":"Xyrem International Study Group","year":"2005","unstructured":"Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005;6(5):415\u201321.","journal-title":"Sleep Med."},{"issue":"8","key":"83_CR53","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/sleep\/29.8.1025","volume":"29","author":"H Murali","year":"2006","unstructured":"Murali H, Kotagal S. Off-label treatment of severe childhood narcolepsy\u2013cataplexy with sodium oxybate. Sleep. 2006;29(8):1025\u20139.","journal-title":"Sleep"},{"issue":"5","key":"83_CR54","doi-asserted-by":"crossref","first-page":"709","DOI":"10.5665\/sleep.1836","volume":"35","author":"M Lecendreux","year":"2012","unstructured":"Lecendreux M, Poli F, Oudiette D, Benazzouz F, Donjacour CE, Franceschini C, et al. Tolerance and efficacy of sodium oxybate in childhood narcolepsy with cataplexy: a retrospective study. Sleep. 2012;35(5):709\u201311.","journal-title":"Sleep"},{"issue":"suppl","key":"83_CR55","first-page":"A233","volume":"37","author":"RK Bogan","year":"2014","unstructured":"Bogan RK, Roth T, Schwartz J, Miloslavsky M, Scharf M. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy [APSS 2014 Abstract 0667]. Sleep. 2014;37(suppl):A233.","journal-title":"Sleep"},{"issue":"7","key":"83_CR56","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/1087054713480033","volume":"17","author":"EJ Modestino","year":"2013","unstructured":"Modestino EJ, Winchester J. A retrospective survey of childhood ADHD symptomatology among adult narcoleptics. J Atten Disord. 2013;17(7):574\u201382.","journal-title":"J Atten Disord"},{"issue":"2","key":"83_CR57","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0022-3565(24)37050-8","volume":"283","author":"DM Edgar","year":"1997","unstructured":"Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther. 1997;283(2):757\u201369.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"83_CR58","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/sleep\/32.11.1425","volume":"32","author":"JA Gruner","year":"2009","unstructured":"Gruner JA, Marcy VR, Lin YG, Bozyczko-Coyne D, Marino MJ, Gasior M. The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep. 2009;32(11):1425\u201338.","journal-title":"Sleep"},{"key":"83_CR59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/NDT.S9749","volume":"6","author":"M Pennick","year":"2010","unstructured":"Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317\u201327.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"83_CR60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1753-2000-3-17","volume":"3","author":"SB Wigal","year":"2009","unstructured":"Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit\/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"83_CR61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1744-9081-6-34","volume":"6","author":"T Wigal","year":"2010","unstructured":"Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.","journal-title":"Behav Brain Funct"},{"issue":"3","key":"83_CR62","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0149-2918(07)80083-X","volume":"29","author":"J Biederman","year":"2007","unstructured":"Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit\/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450\u201363.","journal-title":"Clin Ther"},{"issue":"4","key":"83_CR63","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaac.2011.01.007","volume":"50","author":"RL Findling","year":"2011","unstructured":"Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(4):395\u2013405.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"83_CR64","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4088\/JCP.v69n0903","volume":"69","author":"LA Adler","year":"2008","unstructured":"Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364\u201373.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"83_CR65","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.euroneuro.2012.11.012","volume":"23","author":"D Coghill","year":"2013","unstructured":"Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23(10):1208\u201318.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"83_CR66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-10-0913","volume":"164","author":"CE Donjacour","year":"2011","unstructured":"Donjacour CE, Aziz NA, Frolich M, Roelfsema F, Overeem S, Lammers GJ, et al. Sodium oxybate increases prolactin secretion in narcolepsy patients and healthy controls. Eur J Endocrinol. 2011;164(3):363\u201370.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"83_CR67","doi-asserted-by":"crossref","first-page":"E1069","DOI":"10.1152\/ajpendo.00623.2010","volume":"300","author":"CE Donjacour","year":"2011","unstructured":"Donjacour CE, Aziz NA, Roelfsema F, Frolich M, Overeem S, Lammers GJ, et al. Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. Am J Physiol Endocrinol Metab. 2011;300(6):E1069\u201375.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"Suppl s1","key":"83_CR68","first-page":"45","volume":"21","author":"CEHM Donjacour","year":"2012","unstructured":"Donjacour CEHM, Lammers GJ, Lecendreux M. Endocrine aspects of pharmacotherapy in narcolepsy. J Sleep Res. 2012;21(Suppl s1):45.","journal-title":"J Sleep Res"},{"issue":"8752","key":"83_CR69","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0140-6736(91)92966-6","volume":"337","author":"B Alvarez","year":"1991","unstructured":"Alvarez B, Dahlitz M, Grimshaw J, Parkes JD. Mazindol in long-term treatment of narcolepsy. Lancet. 1991;337(8752):1293\u20134.","journal-title":"Lancet"},{"issue":"1","key":"83_CR70","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.sleep.2012.07.008","volume":"14","author":"N Nittur","year":"2013","unstructured":"Nittur N, Konofal E, Dauvilliers Y, Franco P, Leu-Semenescu S, Cock VC, et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med. 2013;14(1):30\u20136.","journal-title":"Sleep Med"},{"issue":"2","key":"83_CR71","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/cap.2008.036","volume":"19","author":"LR Moller","year":"2009","unstructured":"Moller LR, Ostergaard JR. Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations. J Child Adolesc Psychopharmacol. 2009;19(2):197\u2013201.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"12","key":"83_CR72","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.5664\/jcsm.3284","volume":"9","author":"M Ratkiewicz","year":"2013","unstructured":"Ratkiewicz M, Splaingard M. Treatment of cataplexy in a three-year-old using venlafaxine. J Clin Sleep Med. 2013;9(12):1341\u20132.","journal-title":"J Clin Sleep Med"},{"issue":"4","key":"83_CR73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2869.2003.00380.x","volume":"12","author":"M Lecendreux","year":"2003","unstructured":"Lecendreux M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res. 2003;12(4):347\u20138.","journal-title":"J Sleep Res"},{"issue":"5","key":"83_CR74","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-0030-1267993","volume":"41","author":"S Knudsen","year":"2010","unstructured":"Knudsen S, Mikkelsen JD, Bang B, Gammeltoft S, Jennum PJ. Intravenous immunoglobulin treatment and screening for hypocretin neuron-specific autoantibodies in recent onset childhood narcolepsy with cataplexy. Neuropediatrics. 2010;41(5):217\u201322.","journal-title":"Neuropediatrics"},{"issue":"11","key":"83_CR75","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00415-007-0594-8","volume":"254","author":"R Fronczek","year":"2007","unstructured":"Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol. 2007;254(11):1607\u20138.","journal-title":"J Neurol"},{"issue":"12","key":"83_CR76","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1007\/s00415-008-0996-2","volume":"255","author":"PO Valko","year":"2008","unstructured":"Valko PO, Khatami R, Baumann CR, Bassetti CL. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol. 2008;255(12):1900\u20133.","journal-title":"J Neurol"},{"issue":"16","key":"83_CR77","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.0b013e3181bd1344","volume":"73","author":"Y Dauvilliers","year":"2009","unstructured":"Dauvilliers Y, Abril B, Mas E, Michel F, Tafti M. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology. 2009;73(16):1333\u20134.","journal-title":"Neurology"},{"issue":"1","key":"83_CR78","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1212\/WNL.0b013e31825dce03","volume":"79","author":"S Knudsen","year":"2012","unstructured":"Knudsen S, Biering-Sorensen B, Kornum BR, Petersen ER, Ibsen JD, Gammeltoft S, et al. Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology. 2012;79(1):102\u20133.","journal-title":"Neurology"},{"issue":"1","key":"83_CR79","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.106.111039","volume":"320","author":"X Ligneau","year":"2007","unstructured":"Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther. 2007;320(1):365\u201375.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"83_CR80","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.bcp.2007.01.002","volume":"73","author":"R Parmentier","year":"2007","unstructured":"Parmentier R, Anaclet C, Guhennec C, Brousseau E, Bricout D, Giboulot T, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol. 2007;73(8):1157\u201371.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"83_CR81","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","volume":"163","author":"JC Schwartz","year":"2011","unstructured":"Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713\u201321.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"83_CR82","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","volume":"30","author":"JS Lin","year":"2008","unstructured":"Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin\u2212\/\u2212 mice and patients. Neurobiol Dis. 2008;30(1):74\u201383.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"83_CR83","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","volume":"98","author":"RM Chemelli","year":"1999","unstructured":"Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98(4):437\u201351.","journal-title":"Cell"},{"issue":"11","key":"83_CR84","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","volume":"12","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068\u201375.","journal-title":"Lancet Neurol"},{"issue":"2","key":"83_CR85","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WNF.0b013e318246879d","volume":"35","author":"C Inocente","year":"2012","unstructured":"Inocente C, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reimao R, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy\u2013cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012;35(2):55\u201360.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"83_CR86","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.sleep.2011.06.015","volume":"12","author":"PC Baier","year":"2011","unstructured":"Baier PC, Hallschmid M, Seeck-Hirschner M, Weinhold SL, Burkert S, Diessner N, et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 2011;12(10):941\u20136.","journal-title":"Sleep Med"},{"key":"83_CR87","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbr.2013.12.045","volume":"262","author":"SL Weinhold","year":"2014","unstructured":"Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Goder R, Baier PC. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res. 2014;262:8\u201313.","journal-title":"Behav Brain Res"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-014-0083-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-014-0083-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-014-0083-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:54:05Z","timestamp":1746316445000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-014-0083-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,30]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s40272-014-0083-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,30]]}}}